{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:18:31Z","timestamp":1795043911975,"version":"4.10.2"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.drugalcdep.2022.109751","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T19:03:08Z","timestamp":1672686188000},"page":"109751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran"],"prefix":"10.1016","volume":"243","author":[{"given":"Mehrdad","family":"Khezri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mirzazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Shokoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidar","family":"Sharafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Ghalekhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Mehmandoost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Mousavian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousa","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rezvan","family":"Kakavand-Ghalehnoei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Komasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Gouya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Akbar","family":"Haghdoost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willi","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Karamouzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2022.109751_bib1","first-page":"99","article-title":"An Intervention to Improve HCV Testing, Linkage to Care, and Treatment among People Who Use Drugs in Tehran","volume":"72","author":"Alavi","year":"2019"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugpo.2017.07.002","article-title":"Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review","volume":"47","author":"Bajis","year":"2017","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109751_bib3","first-page":"1","article-title":"Drug consumption rooms (DCRs) as a setting to address hepatitis C\u2013findings from an international online survey","volume":"3","author":"Belackova","year":"2018","journal-title":"Hepatol. Med Policy"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib4","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.drugpo.2014.08.014","article-title":"Prevention, treatment and care of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Bruggmann","year":"2015","journal-title":"Int. J. Drug Policy"},{"issue":"suppl_2","key":"10.1016\/j.drugalcdep.2022.109751_bib5","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109751_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep4.1310","article-title":"Who to test for hepatitis C virus in the Middle East and North Africa?: pooled analyses of 2,500 prevalence measures, including 49 million tests","volume":"3","author":"Chemaitelly","year":"2019","journal-title":"Hepatol. Commun."},{"issue":"12","key":"10.1016\/j.drugalcdep.2022.109751_bib7","first-page":"e1192","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Glob. Health"},{"issue":"7","key":"10.1016\/j.drugalcdep.2022.109751_bib8","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/add.14905","article-title":"The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity?","volume":"115","author":"Ekhtiari","year":"2020","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109751_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-019-0338-y","article-title":"High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011\u20132014: missed opportunities for hepatitis C testing","volume":"17","author":"Enkelmann","year":"2020","journal-title":"Harm Reduct. J."},{"issue":"2","key":"10.1016\/j.drugalcdep.2022.109751_bib10","first-page":"313","article-title":"New treatments have changed the game: hepatitis C treatment in primary care","volume":"32","author":"Facente","year":"2018","journal-title":"Infect. Dis. Clin."},{"key":"10.1016\/j.drugalcdep.2022.109751_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102714","article-title":"Individual and network factors associated with HCV treatment uptake among people who inject drugs","volume":"78","author":"Falade-Nwulia","year":"2020","journal-title":"Int. J. Drug Policy"},{"issue":"S2","key":"10.1016\/j.drugalcdep.2022.109751_bib12","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.2105\/AJPH.2022.306794","article-title":"How substance use treatment services in iran survived despite a dual catastrophic situation","volume":"112","author":"Farhoudian","year":"2022","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109050","article-title":"Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system","author":"Gibbs","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.drugalcdep.2022.109751_bib14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109751_bib15","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030\u2013What will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J. Int AIDS Soc."},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109751_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-020-00431-x","article-title":"Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era","volume":"17","author":"Hariri","year":"2020","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2022.109751_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102837","article-title":"Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: pre and post availability of direct acting antiviral therapy","volume":"83","author":"Iversen","year":"2020","journal-title":"Int. J. Drug Policy"},{"issue":"2","key":"10.1016\/j.drugalcdep.2022.109751_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1520\/JFS14464J","article-title":"Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles","volume":"44","author":"Karch","year":"1999","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.drugalcdep.2022.109751_bib19","doi-asserted-by":"crossref","unstructured":"Kennedy, M.C., Karamouzian, M., Kerr, T., 2017. Public health and public order outcomes associated with supervised drug consumption facilities: a systematic review. Curr HIV\/AIDS Rep 14(5), 161\u2013183.","DOI":"10.1007\/s11904-017-0363-y"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103355","article-title":"Willingness to utilize supervised injection facilities among people who inject drugs in Iran: findings from 2020 national HIV bio-behavioral surveillance survey","volume":"97","author":"Khezri","year":"2021","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib21","first-page":"1","article-title":"HIV Prevalence and Related Behaviors Among People Who Inject Drugs in Iran from 2010 to 2020","author":"Khezri","year":"2022","journal-title":"AIDS Behav."},{"issue":"12","key":"10.1016\/j.drugalcdep.2022.109751_bib22","first-page":"e1208","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet","volume":"5","author":"Larney","year":"2017","journal-title":"Glob. Health"},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109751_bib23","first-page":"1","article-title":"HIV\/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam","volume":"16","author":"Leyna","year":"2019","journal-title":"Tanzan.: Potential HCV \u00c9limin Harm Reduct. J."},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109751_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","article-title":"Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness","volume":"25","author":"MacArthur","year":"2014","journal-title":"Int. J. Drug Policy"},{"issue":"7","key":"10.1016\/j.drugalcdep.2022.109751_bib25","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/add.14944","article-title":"The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa","volume":"115","author":"Mahmud","year":"2020","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.drugalcdep.2022.109751_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249585","article-title":"Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco","volume":"16","author":"Mirzazadeh","year":"2021","journal-title":"Plos One"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib27","article-title":"An On-Site Community-based Model for Hepatitis C Screening, Diagnosis, and Treatment among People Who Inject Drugs in Kerman","volume":"102","author":"Mirzazadeh","year":"2022"},{"issue":"5","key":"10.1016\/j.drugalcdep.2022.109751_bib28","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S2214-109X(16)00068-1","article-title":"Universal health coverage in Iran","volume":"4","author":"Mousavi","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugpo.2016.01.013","article-title":"National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran","volume":"31","author":"Nikfarjam","year":"2016","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib30","first-page":"1","article-title":"Effectiveness of needle\/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs","volume":"2016","author":"Platt","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109751_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-020-00441-9","article-title":"Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis","volume":"18","author":"Rajabi","year":"2021","journal-title":"Harm Reduct. J."},{"issue":"suppl_2","key":"10.1016\/j.drugalcdep.2022.109751_bib32","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/cit302","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"57","author":"Robaeys","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2022.109751_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.drugpo.2019.05.023","article-title":"Integrated models of care for people who inject drugs and live with hepatitis C virus:\u00a0systematic review","volume":"72","author":"Soc\u00edas","year":"2019","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109751_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(14)71045-X","article-title":"Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study","volume":"15","author":"Solomon","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"10.1016\/j.drugalcdep.2022.109751_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002460","article-title":"Respondent-driven sampling for identification of HIV-and HCV-infected people who inject drugs and men who have sex with men in India: a cross-sectional, community-based analysis","volume":"14","author":"Solomon","year":"2017","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.drugalcdep.2022.109751_bib36","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/hep.23220","article-title":"Public health impact of antiviral therapy for hepatitis C in the United States","volume":"50","author":"Volk","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12371","article-title":"Estimates on HCV disease burden worldwide\u2013filling the gaps","volume":"22","author":"Wedemeyer","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.drugalcdep.2022.109751_bib38","series-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib39","series-title":"Combating Hepatitis B and C to Reach Elimination by 2030: advocacy brief","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.drugalcdep.2022.109751_bib40","unstructured":"World Health Organization, 2017a. The epidemiology of hepatitis C virus in the World Health Organization Eastern Mediterranean Region: Implications for strategic action. Eastern Mediterranean hepatitis C virus epidemiology synthesis project."},{"key":"10.1016\/j.drugalcdep.2022.109751_bib41","series-title":"Global Hepatitis Report 2017","author":"World Health Organization","year":"2017"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871622004884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871622004884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:26:30Z","timestamp":1759829190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871622004884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"alternative-id":["S0376871622004884"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109751","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109751"}}